Phase II trial of temsirolimus alone and in combination with irinotecan for KRAS mutant metastatic colorectal cancer: outcome and results of KRAS mutational analysis in plasma

Karen-Lise Garm Spindler; Morten  Sørensen; Niels Pallisgaard; Rikke Andersen; Birgitte Mayland Havelund; John Ploen; Ulrik Lassen; Leif Anders Jakobsen

doi:10.3109/0284186X.2013.776175

Phase II trial of temsirolimus alone and in combination with irinotecan for KRAS mutant metastatic colorectal cancer: outcome and results of KRAS mutational analysis in plasma

Karen-Lise Garm Spindler, Morten Sørensen, Niels Pallisgaard, Rikke Andersen, Birgitte Mayland Havelund, John Ploen, Ulrik Lassen, Leif Anders Jakobsen

61 Citationer (Scopus)

Abstract

Patients with chemotherapy refractory metastatic colorectal cancer and KRAS mutations have no effective treatment option. The present study evaluated the efficacy of temsirolimus in chemotherapy refractory mCRC with KRAS mutations. Furthermore, we wanted to investigate if resistance to temsirolimus could be reversed by the addition of irinotecan. Finally, we analyzed pre-treatment blood samples for KRAS mutations to investigate the association between quantitative measures of KRAS mutated alleles and clinical outcome.

Originalsprog	Engelsk
Tidsskrift	Acta oncologica
Vol/bind	52
Udgave nummer	5
Sider (fra-til)	963-70
Antal sider	8
ISSN	0284-186X
DOI	https://doi.org/10.3109/0284186X.2013.776175
Status	Udgivet - jun. 2013

Adgang til dokumentet

10.3109/0284186X.2013.776175

Andre filer og links

Link to publication in Scopus

Citationsformater

Spindler, K.-L. G., Sørensen, M., Pallisgaard, N., Andersen, R., Havelund, B. M., Ploen, J., Lassen, U., & Jakobsen, L. A. (2013). Phase II trial of temsirolimus alone and in combination with irinotecan for KRAS mutant metastatic colorectal cancer: outcome and results of KRAS mutational analysis in plasma. Acta oncologica , 52(5), 963-70. https://doi.org/10.3109/0284186X.2013.776175

Phase II trial of temsirolimus alone and in combination with irinotecan for KRAS mutant metastatic colorectal cancer: outcome and results of KRAS mutational analysis in plasma. / Spindler, Karen-Lise Garm; Sørensen, Morten ; Pallisgaard, Niels et al.
I: Acta oncologica , Bind 52, Nr. 5, 06.2013, s. 963-70.

Publikation: Bidrag til tidsskrift › Tidsskriftartikel › Forskning › peer review

Spindler, K-LG, Sørensen, M, Pallisgaard, N, Andersen, R, Havelund, BM, Ploen, J, Lassen, U & Jakobsen, LA 2013, 'Phase II trial of temsirolimus alone and in combination with irinotecan for KRAS mutant metastatic colorectal cancer: outcome and results of KRAS mutational analysis in plasma', Acta oncologica , bind 52, nr. 5, s. 963-70. https://doi.org/10.3109/0284186X.2013.776175

@article{c220b081726846fba409cb07800ec6b8,

title = "Phase II trial of temsirolimus alone and in combination with irinotecan for KRAS mutant metastatic colorectal cancer: outcome and results of KRAS mutational analysis in plasma",

abstract = "Patients with chemotherapy refractory metastatic colorectal cancer and KRAS mutations have no effective treatment option. The present study evaluated the efficacy of temsirolimus in chemotherapy refractory mCRC with KRAS mutations. Furthermore, we wanted to investigate if resistance to temsirolimus could be reversed by the addition of irinotecan. Finally, we analyzed pre-treatment blood samples for KRAS mutations to investigate the association between quantitative measures of KRAS mutated alleles and clinical outcome.",

keywords = "Adenocarcinoma, Aged, Antineoplastic Combined Chemotherapy Protocols, Camptothecin, Colorectal Neoplasms, Disease Progression, Drug Resistance, Neoplasm, Female, Humans, Male, Middle Aged, Mutation, Proportional Hazards Models, Proto-Oncogene Proteins, Sirolimus, Treatment Outcome, ras Proteins",

author = "Spindler, \{Karen-Lise Garm\} and Morten S{\o}rensen and Niels Pallisgaard and Rikke Andersen and Havelund, \{Birgitte Mayland\} and John Ploen and Ulrik Lassen and Jakobsen, \{Leif Anders\}",

year = "2013",

month = jun,

doi = "10.3109/0284186X.2013.776175",

language = "English",

volume = "52",

pages = "963--70",

journal = "Acta oncologica ",

issn = "0284-186X",

publisher = "Medical Journals Sweden AB",

number = "5",

}

TY - JOUR

T1 - Phase II trial of temsirolimus alone and in combination with irinotecan for KRAS mutant metastatic colorectal cancer

T2 - outcome and results of KRAS mutational analysis in plasma

AU - Spindler, Karen-Lise Garm

AU - Sørensen, Morten

AU - Pallisgaard, Niels

AU - Andersen, Rikke

AU - Havelund, Birgitte Mayland

AU - Ploen, John

AU - Lassen, Ulrik

AU - Jakobsen, Leif Anders

PY - 2013/6

Y1 - 2013/6

N2 - Patients with chemotherapy refractory metastatic colorectal cancer and KRAS mutations have no effective treatment option. The present study evaluated the efficacy of temsirolimus in chemotherapy refractory mCRC with KRAS mutations. Furthermore, we wanted to investigate if resistance to temsirolimus could be reversed by the addition of irinotecan. Finally, we analyzed pre-treatment blood samples for KRAS mutations to investigate the association between quantitative measures of KRAS mutated alleles and clinical outcome.

AB - Patients with chemotherapy refractory metastatic colorectal cancer and KRAS mutations have no effective treatment option. The present study evaluated the efficacy of temsirolimus in chemotherapy refractory mCRC with KRAS mutations. Furthermore, we wanted to investigate if resistance to temsirolimus could be reversed by the addition of irinotecan. Finally, we analyzed pre-treatment blood samples for KRAS mutations to investigate the association between quantitative measures of KRAS mutated alleles and clinical outcome.

KW - Adenocarcinoma

KW - Aged

KW - Antineoplastic Combined Chemotherapy Protocols

KW - Camptothecin

KW - Colorectal Neoplasms

KW - Disease Progression

KW - Drug Resistance, Neoplasm

KW - Female

KW - Humans

KW - Male

KW - Middle Aged

KW - Mutation

KW - Proportional Hazards Models

KW - Proto-Oncogene Proteins

KW - Sirolimus

KW - Treatment Outcome

KW - ras Proteins

UR - https://www.scopus.com/pages/publications/84877350259

U2 - 10.3109/0284186X.2013.776175

DO - 10.3109/0284186X.2013.776175

M3 - Journal article

C2 - 23514584

SN - 0284-186X

VL - 52

SP - 963

EP - 970

JO - Acta oncologica

JF - Acta oncologica

IS - 5

ER -

Phase II trial of temsirolimus alone and in combination with irinotecan for KRAS mutant metastatic colorectal cancer: outcome and results of KRAS mutational analysis in plasma

Abstract

Adgang til dokumentet

Andre filer og links

Fingeraftryk

Citationsformater